title: Dose-related pharmacologic effects of high dose ara-C and its use in combination with asparaginase for the treatment of patients with acute non-lymphocytic leukemia.
authors.forename: R L
authors.initials: RL
authors.lastname: Capizzi
authors.forename: B L
authors.initials: BL
authors.lastname: Powell
authors.forename: M R
authors.initials: MR
authors.lastname: Cooper
authors.forename: J P
authors.initials: JP
authors.lastname: Rathmell
authors.forename: J C
authors.initials: JC
authors.lastname: White
authors.forename: H B
authors.initials: HB
authors.lastname: Muss
authors.forename: F
authors.initials: F
authors.lastname: Richards
authors.forename: D V
authors.initials: DV
authors.lastname: Jackson
authors.forename: J J
authors.initials: JJ
authors.lastname: Stuart
authors.forename: D R
authors.initials: DR
authors.lastname: White
mesh_terms: D000208:Acute Disease; D000818:Animals; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use* / Q000633:toxicity; D001215:Asparaginase / Q000008:administration & dosage / Q000633:toxicity*; D002286:Carcinoma, Ehrlich Tumor / Q000378:metabolism; D002460:Cell Line; D003561:Cytarabine / Q000008:administration & dosage / Q000378:metabolism / Q000633:toxicity*; D004305:Dose-Response Relationship, Drug; D004351:Drug Resistance; D006801:Humans; D007938:Leukemia / Q000188:drug therapy*; D007940:Leukemia L5178 / Q000378:metabolism; D051379:Mice
chemical_list: D003561:Cytarabine; D001215:Asparaginase